source
- Sarepta tumbles as its gene therapy sales decline furtherEven though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.BioPharma Dive · 2mo ago↗ source
- Key takeaways from WHO briefing on hantavirus cruise ship outbreakHere are key takeaways from a WHO briefing on the hantavirus outbreak aboard a cruise ship.STAT · 2mo ago↗ source
- Seaport’s IPO adventure, obesity pill battles, and Makary’s troublesThis week on "The Readout LOUD" podcast: Seaport Therapeutics’ successful IPO, obesity pill battles, and the FDA commissioner's White House troubles.STAT · 2mo ago↗ source